Editas Medicine Inc
NASDAQ:EDIT
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Editas Medicine Inc
Research & Development
Editas Medicine Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Editas Medicine Inc
NASDAQ:EDIT
|
Research & Development
-$111.2m
|
CAGR 3-Years
12%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-22%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$8.8B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$6.8B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-16%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-13%
|
|
Editas Medicine Inc
Glance View
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 264 full-time employees. The company went IPO on 2016-02-03. The firm is focused on developing transformative gene editing medicines to treat a range of serious diseases. The company has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The firm is focused on both in vivo gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and ex vivo gene-edited cell medicines, in which cells are edited with its technology. The firm's gene editing medicine programs include EDIT-101, EDIT-102, EDIT-103, EDIT-301 and EDIT-202.
See Also
What is Editas Medicine Inc's Research & Development?
Research & Development
-111.2m
USD
Based on the financial report for Sep 30, 2025, Editas Medicine Inc's Research & Development amounts to -111.2m USD.
What is Editas Medicine Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-22%
Over the last year, the Research & Development growth was 50%. The average annual Research & Development growth rates for Editas Medicine Inc have been 12% over the past three years , 3% over the past five years , and -22% over the past ten years .